Skip to main content
Signal8

Swedish Orphan Biovitrum AB (BIOVF)

Sector: Medical - Pharmaceuticals

Industry: Medical - Pharmaceuticals

Swedish Orphan Biovitrum AB logo

Swedish Orphan Biovitrum AB

OTC:BIOVFHealthcare
CLOSED
Mkt Cap$17.77B
EV-
Float181.53M
O/S348M
VOL100 sh
$ Vol$5K
Inst Own-
Net Cash/Sh-
EarningsFeb 4 · in 3mo
Dilution
Historical Data
DateOpenHighLowCloseVolume
Nov 9, 202651.0551.0551.0551.05100
Oct 23, 202645.7245.7245.7245.72110
Oct 21, 202646.0046.0046.0046.00102
Oct 6, 202642.8042.8042.8042.8020,000
Analyst Coverage
Analyst Coverage
ConsensusHold
Price Target
Not available
Ratings Distribution
BUY
0
HOLD
1
SELL
0
TOTAL1
About

Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products.

Its primary therapeutic focus areas encompass hematology, immunology, and a range of genetic and metabolic disorders, with a commercial presence across Europe, North America, and other international markets.

The company's diverse portfolio includes medications addressing critical conditions such as hemophilia B (Alprolix) and hemophilia A (Elocta), thrombocytopenia (Doptelet), hemophagocytic lymphohistiocytosis (Gamifant), and hereditary tyrosinemia type-1 (Orfadin).

Additionally, it provides Kineret for multiple inflammatory diseases, including cryopyrin-associated periodic syndrome, rheumatoid arthritis, and Still's disease, alongside Synagis for severe lower respiratory tract infections. Sobi's broader product range further comprises various other therapeutics like Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. Beyond its proprietary offerings, Sobi is involved in the development of drug substances for external partners, notably ReFacto AF/Xyntha for Pfizer, as well as advancing BIVV001 for hemophilia A and Nirsevimab, which targets respiratory syncytial virus. A key strategic collaboration exists with Apellis Pharmaceuticals Inc. for the co-development of pegcetacoplan, aimed at treating a spectrum of rare diseases, such as paroxysmal nocturnal hemoglobinuria.

The company maintains its headquarters in Solna, Sweden.

Key Metrics
Market Cap$17.77B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 348.00M shares outstanding

SectorHealthcare
IndustryMedical - Pharmaceuticals
ExchangeOTC
CountrySESE
IPO Date-
Shares Outstanding348.00M
Authorized Shares
Float181.53M
52-Week Range
Volume
Average Daily Volume--

30d Avg

--

60d Avg

--

90d Avg

--

Earnings
Dividend History
No dividend history available